Proteomics-based Anticancer Drug Discovery and Development

被引:10
|
作者
Jain, K. K. [1 ]
机构
[1] Jain PharmaBiotech, CH-4057 Basel, Switzerland
关键词
Cancer; proteomics; drug discovery; drug targets; target validation; anticancer drugs;
D O I
10.1177/153303460200100403
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteins are important targets for drug discovery and this applied to cancer as well because there is a defect in the protein machinery of the cell in malignancy. Proteomic technologies are now being integrated with genomic approaches for cancer drug discovery and target validation. Among the large number of proteomic technologies available for this purpose, the most important ones are 3-D protein structure determination, protein microarrays, laser capture microdissection and study of protein-protein and protein-drug interactions. Cancer biomarkers and several cell pathways are important drug targets. Several companies are involved in using proteomic technologies for drug discovery. Finally, proteomic approaches will play an important role in the discovery and development of personalized medicines.
引用
收藏
页码:231 / 236
页数:6
相关论文
共 50 条
  • [1] Using human samples in proteomics-based drug development: bioethical aspects
    Nestler, G
    Steinert, R
    Lippert, H
    Reymond, MA
    EXPERT REVIEW OF PROTEOMICS, 2004, 1 (01) : 77 - 86
  • [2] Proteomics in biomarker discovery and drug development
    He, QY
    Chiu, JF
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 89 (05) : 868 - 886
  • [3] Proteomics-based Development of Biomarker for Prion Diseases
    Choi, Bo-Yeong
    Kim, Su Yeon
    Kim, Chi-Kyeong
    An, Seong Soo
    Lee, Soo Jae
    Ju, Young Ran
    PRION, 2010, 4 (03) : 216 - 216
  • [4] Quantitative Targeted Absolute Proteomics-Based ADME Research as a New Path to Drug Discovery and Development: Methodology, Advantages, Strategy, and Prospects
    Ohtsuki, Sumio
    Uchida, Yasuo
    Kubo, Yoshiyuki
    Terasaki, Tetsuya
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (09) : 3547 - 3559
  • [5] Development and Application of Modification-free Methods for the Proteomics-based Drug Target Identification
    Lyu J.-W.
    Ye M.-L.
    Journal of Chinese Mass Spectrometry Society, 2021, 42 (05) : 845 - 861
  • [7] Statistical Design for Biospecimen Cohort Size in Proteomics-based Biomarker Discovery and Verification Studies
    Skates, Steven J.
    Gillette, Michael A.
    LaBaer, Joshua
    Carr, Steven A.
    Anderson, Leigh
    Liebler, Daniel C.
    Ransohoff, David
    Rifai, Nader
    Kondratovich, Marina
    Tezak, Zivana
    Mansfield, Elizabeth
    Oberg, Ann L.
    Wright, Ian
    Barnes, Grady
    Gail, Mitchell
    Mesri, Mehdi
    Kinsinger, Christopher R.
    Rodriguez, Henry
    Boja, Emily S.
    JOURNAL OF PROTEOME RESEARCH, 2013, 12 (12) : 5383 - 5394
  • [8] Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid
    Lourenco, A. S. T.
    Baldeiras, I.
    Graos, M.
    Duarte, C. B.
    CURRENT MOLECULAR MEDICINE, 2011, 11 (04) : 326 - 349
  • [9] Editorial: Mass spectrometry-based proteomics in drug discovery and development
    Pejchinovski, Martin
    Magalhaes, Pedro
    Metzger, Jochen
    FRONTIERS IN MEDICINE, 2024, 11
  • [10] Proteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities
    Lopez Villar, Elena
    Wu, Duojiao
    Cho, William C.
    Madero, Luis
    Wang, Xiangdong
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2014, 18 (07) : 1239 - 1246